Education
About Us
Working with TipRanks
Follow Us
AEON Biopharma (AEON)
:AEON
AEON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.38 - $402.48
Previous CloseN/A
Volume17.80M
Average Volume (3M)597.63K
Market Cap
$4.53M
Enterprise Value$34.53M
Total Cash (Recent Filing)$9.75M
Total Debt (Recent Filing)$131.53M
Price to Earnings (P/E)<0.1
Beta1.70
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)68.69
Shares Outstanding10,532,802
10 Day Avg. Volume317,580
30 Day Avg. Volume597,626
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.12
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap7.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.93
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
AEON Biopharma News
PremiumCompany Announcements
AEON Biopharma Appoints New CEO Robert Bancroft
PremiumCompany Announcements
AEON Biopharma Appoints Jost Fischer as Interim CEO
PremiumCompany Announcements
AEON Biopharma’s Strategic Progress and Financial Turnaround
PremiumCompany Announcements
AEON Biopharma Announces CEO Resignation and Interim Appointment
PremiumCompany Announcements
AEON Biopharma Releases New Corporate Presentation
---
Bulls Say, Bears Say
Bulls Say
Cost ManagementR&D expenses declined 50.8% YoY to $4.4M, which were below the estimate, indicating effective cost management.
Regulatory ApprovalAeon finds alignment with the FDA on key biosimilar pathway requirements, boosting confidence in potential regulatory approval.
Bears Say
Funding UncertaintyGiven the uncertainty in funding, the price target is adjusted to $5 from $6, reflecting potential financial challenges.
Production DependencyAeon relies on Daewoong to manufacture ABP-450, and any production issues with Daewoong could adversely impact Aeon.
---
Ownership Overview
14.50% Insiders
9.66% Mutual Funds
7.96% Other Institutional Investors
75.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AEON FAQ
What was AEON Biopharma’s price range in the past 12 months?
AEON Biopharma lowest stock price was $0.38 and its highest was $402.48 in the past 12 months.
What is AEON Biopharma’s market cap?
AEON Biopharma’s market cap is $4.53M.
When is AEON Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were AEON Biopharma’s earnings last quarter?
AEON Biopharma released its earnings results on Nov 13, 2024. The company reported -$11.52 earnings per share for the quarter, the consensus estimate of -$11.52 by $0.
Is AEON Biopharma overvalued?
According to Wall Street analysts AEON Biopharma’s price is currently Overvalued.
Does AEON Biopharma pay dividends?
AEON Biopharma does not currently pay dividends.
What is AEON Biopharma’s EPS estimate?
AEON Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AEON Biopharma have?
AEON Biopharma has 10,532,802 shares outstanding.
What happened to AEON Biopharma’s price movement after its last earnings report?
AEON Biopharma reported an EPS of -$11.52 in its last earnings report, expectations of -$11.52. Following the earnings report the stock price went down -6.944%.
Which hedge fund is a major shareholder of AEON Biopharma?
Among the largest hedge funds holding AEON Biopharma’s share is Saba Capital Management. It holds AEON Biopharma’s shares valued at 0.
---
Company Description
AEON Biopharma
AEON Biopharma (AEON) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapeutic treatments targeting neurological and gastroenterological disorders. The company is engaged in the research and development of therapeutic applications for botulinum toxin complex, aiming to address unmet medical needs in various indications such as chronic migraine, cervical dystonia, and other related conditions.
---
AEON Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Oruka Therapeutics
―
Cytokinetics
―
Rigel
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Atara Biotherapeutics
―
Best Analysts Covering AEON
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-93.53%
reiterated a buy rating 7 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -93.53% per trade.
---